clinical trial · NCT07406347
A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age
GlaxoSmithKline·phase1·not yet recruiting·n = 60
Pneumonia, BacterialPn-MAPS30plusPCV20
brief summary
The main purpose of this study is to evaluate safety and reactogenicity of the investigational pneumococcal vaccine (called Pn-MAPS30plus). PCV20 will be used as a comparator for this study
started
Jul 10, 2026
primary completion
Apr 3, 2028
completion
Apr 3, 2028
last updated
Feb 12, 2026
official title
A Phase 1, Observer-blind, Randomized, Active Controlled Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol